… Recurrent cancer was noted in 40 patients, four while receiving erlotinib treatment and 36
after stopping erlotinib (Appendix Table A1, online only). The median time to recurrence after …

… erlotinib treatment. The differences in characteristics between those who continued erlotinib
therapy and those who did not continue erlotinib … would benefit from erlotinib therapy beyond …

… erlotinib. Extracellular binding of ligands like the epidermal growth factor (EGF) and transforming
growth factor-… survival, 31% of patients treated with erlotinib in this study were alive at 1 …

… Phase II and III trials at Cancer Institutes of Canada have demonstrated around 12%
diminution in lung cancer symptoms in NSCLC patients following erlotinib treatment [62]. In the …

… Erlotinib is one of the treatment choices for patients with advanced non‑small cell lung …
epidermal growth factor receptor (EGFR) mutation status. However, its efficacy for the treatment of …

… -dose) erlotinib and continuous daily (low-dose) erlotinib as an initial treatment for patients
with EGFR-mutant lung cancers. We defined the maximum tolerated dose of erlotinib as 1200 …

… We therefore hypothesized that cells treated with patritumab could overcome erlotinib
resistance induced by heregulin. To test this, heregulin-overexpressing PC9 cells were …

… approved by US-FDA for the treatment of Non-Small Cell Lung Cancer (NSCLC) and
Pancreatic Cancer. Erlotinib inhibited epidermal growth factor receptor (EGFR) that blocks tumor …

… to be maintained on erlotinib treatment at the lowest dose that keeps them in remission, as
long as no considerable adverse effects are observed. Treatment resistance, as observed in …

… vascular endothelial growth factor pathways are … growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) resistance. We hypothesized that treatment with cabozantinib plus erlotinib …